节点文献
新型抗骨质疏松药物雷尼酸锶
A new antiosteoporotic agent-strontinm ranelate
【摘要】 雷尼酸锶是第一个具有双重药理作用的抗骨质疏松新药,在保持骨形成的同时抑制骨吸收,具有安全、耐受性好且服用方便等特点。现对其药理作用、药动学、临床评价及安全性等做一综述。
【Abstract】 Strontium ranelate is licensed for the treatment of postmenopausal osteoporosis to re- duce the risk of vertebral and hip fractures.It has a novel mode of dual actions,both increasing bone for- mation and reducing bone resorption.Its advantages include well tolerated,less adverse effects and easy to use.This paper reviews the pharmacology,pharmacokinetics,clinical evaluation and safety profile of strontium ranelate.
【关键词】 雷尼酸锶;
骨质疏松;
双重药理作用;
【Key words】 strontium ranelate; osteoporosis; dual actions of pharmacology;
【Key words】 strontium ranelate; osteoporosis; dual actions of pharmacology;
- 【文献出处】 中国新药杂志 ,Chinese Journal of New Drugs , 编辑部邮箱 ,2007年09期
- 【分类号】R977
- 【被引频次】10
- 【下载频次】393